Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140, and CDX-3379.
| Website: | www.celldex.com |
| Email: | ir@celldextherapeutics.com |
| Main Phone: | +1 908 200-7500 |
| Address: | 53 Frontage Road |
| Address 2: | Suite 220 |
| State: | NJ |
| City / Town: | Hampton |
| Country: | USA |
| Postal Code: | 08827 |
| Exchange: | NSC |
| CEO: | Anthony S. Marucci |
| Employees: | 135 |
| NAICS: | In-Vitro Diagnostic Substance Manufacturing(325413) |
Gathering Data... Please wait Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140, and CDX-3379.
| Website: | www.celldex.com |
| Email: | ir@celldextherapeutics.com |
| Main Phone: | +1 908 200-7500 |
| Address: | 53 Frontage Road |
| Address 2: | Suite 220 |
| State: | NJ |
| City / Town: | Hampton |
| Country: | USA |
| Postal Code: | 08827 |
| Exchange: | NSC |
| CEO: | Anthony S. Marucci |
| Employees: | 135 |
| NAICS: | In-Vitro Diagnostic Substance Manufacturing(325413) |
| Last Price 2.56 | Change $ 0.03 | Change % 1.19 | Tick N/A |
| Bid 2.52 | Bid Size 12,200.00 | Ask 2.64 | Ask Size 1,000.00 |
| Open 2.56 | High 2.56 | Low 2.56 | Prev Close 2.53 |
| Last Trade | Volume 1,617 | 52 Wk Hi 11.62 | 52 Wk Low 2.40 |
| Market Cap 35.2 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 13,768,878.00 | EPS (TTM) -4.04 | PE Ratio N/A | Exchange NCM |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 3 | 18 |
| Number of Buys | 0 | 7 |
| Number of Sells | 3 | 11 |
| Net Activity | -9005 | 34783 |
| Last 10 Buys | Shares |
|---|---|
| Tibor Keler | 1,000 |
| Larry Ellberger | 1,000 |
| Larry Ellberger | 1,000 |
| Larry Ellberger | 1,000 |
| Larry Ellberger | 1,000 |
| Larry Ellberger | 1,000 |
| Larry Ellberger | 1,000 |
| Anthony S. Marucci | 1,000 |
| Tibor Keler | 1,000 |
| Avery W. Catlin | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| Avery W. Catlin | 1,000 |
| Avery W. Catlin | 1,000 |
| Avery W. Catlin | 1,000 |
| Larry Ellberger | 1,000 |
| Harry H. Penner | 1,000 |
| Karen L. Shoos | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 3 | 3 | 3 | 3 |
| Low Target Price Estimate | 1 | 1 | 1 | 1 |
| Mean Target Price Estimate | 2.05 | 2.05 | 2.05 | 2.05 |
| Standard Deviation | 1 | 1 | 1 | 1 |
| Date of Most Recent Estimate | 05/22/18 | 05/22/18 | 05/22/18 | 05/22/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 8-K | Report of unscheduled material events or corporate changes. | 3 | 2018-06-14 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-04 |
| 8-K | Report of unscheduled material events or corporate changes. | 3 | 2018-06-01 |
| SC 13G/A | Amendment to the SC 13G filing | 1 | 2018-05-10 |
| 10-Q | Quarterly report with a continuing view of a company's financial position | 51 | 2018-05-10 |
| 8-K | Report of unscheduled material events or corporate changes. | 4 | 2018-05-10 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-02 |
| DEF 14A | Official notification to shareholders of matters to be brought to a vote (Proxy) | 62 | 2018-04-30 |
| 8-K | Report of unscheduled material events or corporate changes. | 3 | 2018-04-24 |
| CT ORDER | 1 | 2018-04-20 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 1 | 1 | 3 | 3 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 3 | 3 | 1 | 2 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 2.5 | 2.5 | 1.5 | 1.8 |
© 2019 Equities
* All dates and time are being displayed in Eastern Standard Time (EST).
